ReviewEuropean journal of immunology2026
Endothelial Atypical Receptors for Chemoattractants in Lung Immune Surveillance.
Review in European journal of immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Chemokines and their receptors play a pivotal role in the initiation and regulation of inflammation through the orchestration of leukocyte extravasation and directed migration toward sites of tissue injury. Tight control of chemokine gradients within tissues is essential to ensure that inflammatory responses remain transient and properly resolved. When this regulatory mechanism fails, dysregulated chemokine signaling can contribute to the development of chronic inflammation. Atypical receptors for chemoattractants comprise atypical chemokine receptors (ACKRs) and the chemerin-presenting receptor CCRL2. ACKRs perform specialized functions enabling the fine-tuning of chemokine gradients, primarily through the scavenging, sequestration, or redistribution of chemokines. By regulating their spatial and temporal availability, ACKRs play a key role in limiting excessive leukocyte recruitment and promoting inflammation resolution. The lungs are in a dynamic equilibrium between immune activation and homeostasis. Rapid and tightly regulated immune cell recruitment is essential for effective host defense while preventing tissue damage. In this context, ACKRs expressed by specialized lung endothelial cells are emerging as critical regulators of leukocyte trafficking and inflammatory resolution. Given the paucity of studies in this area, this review summarizes current knowledge of ACKRs and CCRL2 in lung immune surveillance and discusses their potential as therapeutic targets in lung diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.